White House and Trump secure lower prices for obesity drugs and influence on international actions
President Trump announced deals with Eli Lilly and Novo Nordisk to significantly reduce the out-of-pocket costs of weight loss drugs, including GLP-1 injections like Wegovy and Zepbound, with prices potentially dropping to as low as $50 to $350 per month depending on coverage and dosage, expanding access through Medicare, Medicaid, and direct-to-consumer platforms.